PRCC
PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.
Overview
May regulate cell cycle progression through interaction with MAD2L2.
Open Targets scores its association with cancer at 0.54 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.23, somatic mutation 0.80).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.
- 1 · What it is
PRCC (Proline-rich protein PRCC) is a gene. The public catalogues list it as a fusion partner, and the evidence so far is association rather than a proven role.
- 2 · What goes wrong in cancer
May regulate cell cycle progression through interaction with MAD2L2. Location: Nucleus (UniProt).
- 3 · How drugs use it
No product in this corpus aims at PRCC yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
External identifiers
Sources: HGNC HGNC:9343 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92733 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000143294 (association with cancer (MONDO_0004992) 0.54; (GraphQL API, CC0))
Biology
May regulate cell cycle progression through interaction with MAD2L2. Location: Nucleus (UniProt). Locus 1q23.1 (HGNC).
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "association-only" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PRCC" OR ABSTRACT:"PRCC" OR TITLE:"proline rich mitotic checkpoint control factor" OR ABSTRACT:"proline rich mitotic checkpoint control factor" OR TITLE:"Proline-rich protein PRCC" OR ABSTRACT:"Proline-rich protein PRCC" OR TITLE:"RCCP1" OR ABSTRACT:"RCCP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRCC, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentSavolitinib
Shares Savolitinib vs. Sunitinib in MET-driven PRCC., Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC.
- CancerPapillary renal cell carcinoma
Shares Savolitinib vs. Sunitinib in MET-driven PRCC., Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC.
- TreatmentSunitinib
Shares Savolitinib vs. Sunitinib in MET-driven PRCC., Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC.